Trial Profile
A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2012
Price :
$35
*
At a glance
- Drugs Semaxanib (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer; SUGEN
- 01 Feb 2010 New trial record